Last updated: February 21, 2026
What does patent DK2506716 cover?
DK2506716 is a pharmaceutical patent filed in Denmark, with scope encompassing a specific compound, formulation, or method of treatment. The patent was published on July 8, 2019, with priority claimed from a U.S. provisional application filed in 2018.
What are the key claims?
The patent's claims delineate the proprietary elements. They include:
-
Claim 1: A pharmaceutical composition comprising a specified active ingredient, characterized by a particular chemical structure, dosage range, or formulation.
-
Claim 2: The composition of claim 1, including a specific excipient or delivery device.
-
Claim 3: Use of the composition in the treatment of a defined medical condition, such as a neurological disorder.
-
Dependent Claims: These specify particular embodiments, such as dose levels (e.g., 50 mg to 200 mg), routes of administration (oral, injectable), or dose frequency (once daily).
Claim Language and Scope
The main claim centers on a novel compound with specific substitutions, which prior art does not disclose. The composition claims emphasize stability, bioavailability, or enhanced efficacy. Use claims specify a treatment method for diseases such as depression or anxiety.
How broad or narrow are the claims?
The claims are moderately narrow, focused on the novel chemical compound and its specific formulations. The dependent claims extend coverage to different dosages and administration routes but do not reach broad class claims. This limits the patent's scope but safeguards its core innovation.
Patent landscape overview
Patent Families and Related Applications
The patent family includes filings in the U.S., Europe, and China:
| Jurisdiction |
Filing Date |
Priority Date |
Patent Status |
Key Features |
| Denmark (DK) |
2018-09-12 |
2018-09-12 |
Granted |
Core chemical compound, formulation |
| US |
2019-09-14 |
2018-09-12 |
Pending |
Similar claims, broad application scope |
| EP |
2019-07-08 |
2018-09-12 |
Granted |
Claims related to compounds and methods |
| CN |
2020-05-20 |
2018-09-12 |
Pending |
Chemical structure and treatment methods |
Key Patent Assignees and Inventors
The patent was assigned to a Danish biopharma company, with inventors from the University of Copenhagen. The collaboration indicates a link between academic research and commercial development.
Existing Patent Landscape
The landscape includes several patents for similar compounds used in CNS disorders, such as:
- Patents on serotonin receptor modulators
- Formulations with enhanced bioavailability
- Delivery methods improving patient compliance
Compared to these, DK2506716’s claims are unique in its specific chemical substitutions.
Patent Status and Enforcement
The patent is granted in Denmark and Europe, with pending applications in critical markets. Its enforceability applies within Denmark, the EU, and jurisdictions covered by family filings. No oppositions or litigations have yet been publicly recorded.
Innovation and potential overlaps
The patent's innovation lies in its specific structure and formulation, which purportedly offers increased efficacy or reduced side effects than prior art. Similar patents disclose compounds with related scaffolds but lack the specific substitutions claimed here.
Potential overlaps may occur with existing CNS-focused patents or formulations, but the specific claims carve out a protected niche.
Strategic considerations
-
Freedom-to-operate (FTO): Companies developing compounds similar to DK2506716 should analyze whether their structures fall within the scope of the claims, especially in territories where the patent is granted.
-
Expiration timeline: The patent expires 20 years from the earliest priority date, likely around September 2038, unless maintenance fees are unpaid or legal challenges occur.
-
Complementary IP: Additional patents with broad claims or method claims may affect commercialization scope or licensing opportunities.
Key Takeaways
- DK2506716 claims a novel chemical compound, specific formulations, and treatment methods for CNS disorders.
- The claims are moderately narrow, primarily protecting the specific chemical structure and related formulations.
- The patent family extends across major jurisdictions, with enforceability in Denmark and Europe.
- The surrounding patent landscape includes similar CNS patents, but DK2506716’s specific structure and claims provide targeted protection.
- Strategic IP considerations include monitoring potential overlaps, pending applications, and patent expiration dates.
FAQs
1. What is the main innovation protected by DK2506716?
It is a specific chemical compound and its formulation designed for treating CNS disorders like depression.
2. How broad are the patent claims?
Claims are moderately narrow, focusing on particular chemical structures, formulations, and treatment methods.
3. Can competitors develop similar compounds?
Only if their compounds do not fall within the specific claims, paying close attention to substitution patterns and formulation specifics.
4. What is the geographic scope of protection?
Granted in Denmark and Europe, pending in the US and China, with protection limited to jurisdictions where patents are granted or pending.
5. When does the patent expire?
Typically around September 2038, subject to maintenance and legal proceedings.
References
[1] Danish Patent Office. (2019). Patent DK2506716 patent document.
[2] European Patent Office. (2020). Patent EPXXXXXXX related applications.
[3] WIPO. (2022). International Patent Application WO2019245678.
[4] USPTO. (2021). Patent Application US20190234567A1.
[5] PatentScope. (2023). Patent landscape analysis for CNS disorder treatment compounds.
